THE BIOLOGY AND TREATMENT OF HUMAN LEUKEMIA AND LYMPHOMA

在这个建议中，我们再次强调了人类的生物学 白血病和淋巴瘤细胞，并详细介绍了成就， 在该项目的第二年期间发生了。 的 整合基础研究， 造血干细胞和造血细胞通过免疫学，细胞学， 细胞培养技术已经对我们的临床 治疗方案。 在未来一年，我们将继续发展 细胞表面和分子探针用于表征早期T细胞 利用我们对T细胞受体基因的理解， 重新安排 此外，我们亦会继续研究 正常骨髓干细胞及其白血病克隆形成细胞鉴定 利用免疫学、细胞遗传学和分子探针的同行。 单克隆抗体已被证明是非常重要的， 诊断和越来越多的证据将获得支持的概念， 可以为B细胞和 骨髓性白血病 自体骨髓移植计划与J2和 J5将继续进行，因为迄今为止的数据表明， 与在同种异体匹配系统中获得的相比是有利的。 B1方案的研究表明，它是一种主要的新治疗方法， 在以前无反应的非霍奇金淋巴瘤的方式。 抗B-lym 肽抗体将用于分离和表征 B-lym抗原，希望这些新的试剂类别将 补充现有的抗体用于白血病的表征。 Drs. Kufe、Faller和Frei已经证明了新的药理学方法， 可以优化AML、ALL和其他肿瘤的治疗。 这些 研究将继续利用联合化疗， 自体移植残余肿瘤的细胞免疫治疗，门冬酰胺酶 治疗ALL和低剂量阿糖胞苷。 Sallan博士取得的进展， Weinstein和Mayer使用化疗治疗ALL和AML 和免疫疗法给大多数这些疾病 最终是可以治愈的 目前的计划导致了多个 对免疫学、分子生物学和生物学有兴趣的个人之间的相互作用 生物学、细胞表面抗原、药理学、血液学和肿瘤学。 我们 相信这种癌症治疗和诊断的综合方法 已经导致了对恶性细胞及其 控制

In this proposal we have once again emphasized the biology of human leukemia and lymphoma cells and have detailed the accomplishments which have taken place during the course of the second year of this project. The integration of basic studies involving the characterization of hematopoietic stem cells and hematopoietic cells by immunologic, cytologic, and cell culture techniques has already had an impact on our clinical treatment programs. In the next year, we will pursue the development of cell surface and molecular probes for the characterization of the early T cell malignancies utilizing our understanding of T cell receptor gene rearrangements. In addition, we will pursue studies directed at the identification of normal myeloid stem cells and their leukemic clonogenic counterparts utilizing immunologic, cytogenetic and molecular probes. Monoclonal antibodies have proved to be extraordinarily important for diagnosis and increasing evidence will be obtained to support the notion that prognostically important groups can be defined for both B cell and myeloid leukemias. Autologous bone marrow transplant program with J2 and J5 will be continued since the data to date indicates that this approach compares favorably to that obtained in the allogeneic matched system. Studies with the B1 protocol indicate it to be a major new therapeutic modality in previously unresponsive non-Hodgkins's lymphomas. Anti-B-lym peptide antibodies will be utilized for the isolation and characterization of B-lym antigens and it is hoped that these new classes of reagents will complement existing antibodies for the characterization of leukemias. Drs. Kufe, Faller and Frei have demonstrated new pharmacologic approaches which can optimize the treatment of AML, ALL and other tumors. These investigations will continue to exploit combination chemotherapy for the cytoirradication of residual tumor in autologous transplants, asparaginase treatment for ALL and low dose ara-C. Progress made by Drs. Sallan, Weinstein and Mayer in the treatment of ALL and AML utilizing chemotherapy and immunotherapy lend hope to the view that the majority of these diseases will be ultimately curable. The present program has led to multiple interactions of individuals with interests in immunology, molecular biology, cell surface antigens, pharmacology, hematology and oncology. We believe that this integrated approach to cancer treatment and diagnosis has already resulted in a greater understanding of the malignant cell and its control.